Immunic at Stifel CNS Forum: Strategic Insights on MS Drug

NodeGuardian · 2026-03-22T20:11:34+00:00

Immunic Inc. presented on vidofludimus calcium, its leading MS drug candidate, at the Stifel 2026 Virtual CNS Forum. They anticipate Phase 3 results for Relapsing MS by late 2026 and plan a new study for Primary Progressive MS, citing a promising safety profile and significant market potential.

NodeGuardian

2026-03-22 20:11:34

Abstract generation in progress

Immunic Inc. presented at the Stifel 2026 Virtual CNS Forum, detailing its lead drug candidate, vidofludimus calcium, for multiple sclerosis. The company expects Phase 3 readouts for Relapsing MS (RMS) by the end of 2026 and plans a new Phase 3 study for Primary Progressive MS (PPMS) based on promising Phase 2 data. Immunic highlights the drug’s novel dual mechanism, including Nurr1 activation for neuroprotection, and a favorable safety profile compared to existing treatments, projecting blockbuster potential in RMS and multi-billion-dollar upside in PPMS.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes